Abstract
Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Infectious Disorders - Drug Targets
Title:Tuberculosis Vaccines: Hopes and Hurdles
Volume: 13 Issue: 5
Author(s): Mohamed J. Ahsan, Shiv K. Garg, Bharat Vashistha and Piush Sharma
Affiliation:
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Abstract: Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Export Options
About this article
Cite this article as:
Ahsan J. Mohamed, Garg K. Shiv, Vashistha Bharat and Sharma Piush, Tuberculosis Vaccines: Hopes and Hurdles, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526513666131201125513
DOI https://dx.doi.org/10.2174/1871526513666131201125513 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies Expression, Purification and Characterisation of Haemophilus influenzae 3-Isopropylmalate Dehydrogenase (LeuB)
Protein & Peptide Letters Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism Ligand and Structure Based Models for the Identification of Beta 2 Adrenergic Receptor Antagonists
Current Computer-Aided Drug Design Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Microwave: An Important and Efficient Tool for the Synthesis of Biological Potent Organic Compounds
Current Medicinal Chemistry Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences The Battle for Iron between Humans and Microbes
Current Medicinal Chemistry Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biotechnology Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design Predicting Subcellular Localization of Mycobacterial Proteins by Using Chous Pseudo Amino Acid Composition
Protein & Peptide Letters Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Editorial [(Poly)phenol Chemistry: Part II - Physicochemical Properties & Biological Implications (Guest Editor: Stefan Chassaing)]
Current Organic Chemistry Bedside Balance Testing in Elderly People
Current Aging Science Delivery of Anti-Viral Nucleoside Analogues to the Central Nervous System
Current Medicinal Chemistry - Anti-Infective Agents